Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 917 citations

Medicine, Pharmacology, Pharmacotherapy +15

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 794 citations

Medicine, Oncology, Pharmacology +17

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 346 citations

Medicine, Oncology, Pharmacology +17

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan et al. · The Lancet Oncology · 2017 · 295 citations · Full text

Medicine, Oncology, Pharmacotherapy +11